Danish pharma giant Novo to use Anthropic's Claude to advance AI drug discovery (www.euronews.com)

Danish pharmaceutical giant Novo has announced a partnership with Anthropic to leverage their AI model, Claude, in advancing drug discovery and development. This collaboration aims to enhance Novo's research and development capabilities by integrating AI tools that can provide new scientific insights and accelerate the creation of transformative health solutions. Novo's CEO, Mike Doustdar, emphasized that this partnership will not only increase productivity in R&D but also potentially compress decades of medical advancements into a much shorter timeframe. The significance of this collaboration lies in the ongoing trend of pharmaceutical companies adopting AI to revolutionize their research processes. Anthropic’s Claude Science will enable Novo researchers to harness advanced scientific reasoning, improving their understanding of human biology and drug interactions. With the ability to analyze complex datasets and identify potential drug candidates, this partnership joins Novo's previous initiatives, such as its use of OpenAI's science GPT-Rosalind and its cooperation with Nvidia on Denmark's first AI-ready supercomputer. As AI capabilities expand, these advancements could dramatically shorten research timelines and enhance patient outcomes.